Phathom Pharmaceuticals, Inc. EBIT Margin

EBIT Margin of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.


Highlights and Quick Summary

  • EBIT Margin for the quarter ending September 29, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT Margin decreased by NaN%
  • Annual EBIT Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual EBIT Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month EBIT Margin ending September 29, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing EBIT Margin decreased by NaN% year-over-year
Trailing EBIT Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of Phathom Pharmaceuticals, Inc.

Most recent EBIT Marginof PHAT including historical data for past 10 years.

Interactive Chart of EBIT Margin of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0% 0.0% 0.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0% 0.0% 0.0% 0.0%
2018 0.0% 0.0%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.